Phase I of Kai Tak Station Square and Kai Tak Avenue Park to open tomorrow (with photos)
****************************************************************************************
The Leisure and Cultural Services Department (LCSD) announced today (December 6) that the newly built Phase I of Kai Tak Station Square (KTSS) and Kai Tak Avenue Park (KTAP) in Kowloon City District will open for public use from tomorrow (December 7). Located at the heart of Kai Tak town centre, the square and park will be a pleasant and relaxing leisure space with a soft landscaping environment for public enjoyment.
Occupying about 3.5 hectares at the north apron of the former Kai Tak Airport, Phase I of KTSS link between the Kai Tak MTR Station and provides a spacious and quality open plaza and lawn.
Adjacent to KTSS with an area of around 3.2 hectares, KTAP provides diversified recreational facilities to meet the needs of people of all ages. Facilities include thematic gardens, a children’s play area, fitness equipment and a basketball court.
Members of the public who plan to visit KTSS and KTAP can walk from Exit A of the Kai Tak MTR Station, or take various bus and minibus routes there. For enquiries, please contact the Kowloon City District Leisure Services Office of the LCSD at 2711 0541 during office hours.
Nov 13, 2021 | Business
Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer’s disease. Reductions in plasma p-tau181 were also correlated with a lowering of amyloid beta plaque. The pre-specified analysis of plasma samples was conducted by an independent lab, drawing from the two pivotal ADUHELM Phase 3 EMERGE and ENGAGE trials. The findings were presented today at the Clinical Trials on Alzheimer’s Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts.
The analysis highlighted that ADUHELM significantly reduced tau pathology, a defining feature of Alzheimer’s disease, as measured by plasma p-tau181, when compared to placebo. The effect was greater with higher doses and longer duration of ADUHELM treatment. Greater reduction in plasma p-tau181 also had a statistically significant correlation with less decline in cognition and function in ADUHELM-treated patients. Furthermore, the analysis demonstrated a statistically significant correlation between change in plasma p-tau181 and lowering of amyloid beta plaque, showing the effect of ADUHELM on the two core pathological features of Alzheimer’s disease.
“We now have robust and concordant data that ADUHELM has effect on two core defining pathologies of Alzheimer’s disease, and substantial evidence of treatment correlation between changes in plasma p-tau181 and the slowing of disease progression,” said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen. “We are committed to continuing to generate data, and we believe these new findings can help inform treatment choice and advance Alzheimer’s research including in diagnosis and disease monitoring.”
The findings showed that ADUHELM significantly lowered plasma p-tau181 in a dose- and time-dependent manner vs. placebo in both Phase 3 trials. In the EMERGE high-dose group, p-tau decreased 13% from baseline (p
Greater reduction in plasma p-tau181 was correlated with less clinical decline in all four clinical outcome measures in the Phase 3 trials. Correlation values across these endpoints were as follows for EMERGE and ENGAGE, respectively: Clinical Dementia Rating Sum of Boxes Score (CDR-SB) R = 0.11 (p=0.0166) and R = 0.14 (p = 0.0005); Mini-Mental State Examination (MMSE) R = -0.21 (p
Changes in plasma p-tau181 was also significantly correlated with change in amyloid beta positron emission tomography (PET) standardized uptake value ratio (SUVR): EMERGE R = 0.38, p
“These data not only show an important link between the ability of ADUHELM to clear amyloid beta plaque and reduce plasma p-tau levels, but also significantly correlate those reductions with slowing cognitive decline,” said Oskar Hansson, M.D., Ph.D., Professor of Neurology at Lund University and Skane University Hospital, Sweden, who led the oral late-breaker presentation at the CTAD conference. “Having research from nearly two thousand patients provides invaluable insights into the dynamics of the interconnected pathologies within this complex disease.”
The two pathological hallmarks of Alzheimer’s disease–amyloid beta plaque and neurofibrillary tangles (composed of abnormal p-tau)–disrupt communication between neurons, which leads to the loss of brain function, as well as neurodegeneration and clinical decline, which can begin in the early stages of Alzheimer’s disease.
Biogen also presented data from the Phase 3b redosing study, EMBARK, which examined the impact of patients with Alzheimer’s disease stopping ADUHELM treatment for an extended period of time (average length of 1.7 years) before re-initiating treatment. The study showed that reductions in amyloid beta plaque were maintained in the high-dose group during the treatment gap period compared to the placebo group. Although the disease continued to progress after treatment discontinuation, numerical differences in favor of ADUHELM were maintained across clinical endpoints.
The EMBARK baseline data underscore that further scientific evidence is needed to better understand the impact of discontinuation from anti-amyloid treatment and the role that other underlying pathological processes may play in disease progression.
EMBARK is not a randomized study and there may be selection bias for the enrolling patients; Interpretation of these data must weigh the potential influence of the heterogeneity of dose, duration of exposure, and treatment gap periods across individuals in the study. The analysis is from the largest clinical trial dataset available in early Alzheimer’s disease, which included 1,856 screened patients from EMERGE, ENGAGE, PRIME and EVOLVE.
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Mar 10, 2021 | International, Sports
The Leisure and Cultural Services Department (LCSD) will launch a new phase of the Online Interactive Sports Training Programmes in April. Enrolment for the programmes will be open from March 17 (Wednesday).
The Online Interactive Sports Training Programmes are conducted by coaches through an online platform in real time, enabling participants to learn interactively and practise physical activities at home, and to establish a healthy lifestyle. Ten types of sports programmes will be offered. They are aerobic dance, fitness exercise, “Body-mind Stretch”, parent-child fitness, tai chi, fitness yoga and “Hip Hop Dance” as well as the newly organised courses on badminton, “Play Tennis” and table tennis, introducing the basic grip, shuttlecock or ball control, footwork and physical co-ordination skills of these games. Participants who complete the online classes of these three types of games will be invited to attend a practical session to practice the skills learned in the programmes. The courses are designed by relevant national sports associations and are suitable for people of all ages.
Participants can join the online courses at home by using their desktop or tablet computers or their mobile phones, with Zoom software downloaded in advance. Both daytime and night-time courses will be held, with each course consisting of two or three one-hour sessions.
Members of the public can enrol on a first-come, first-served basis from 8.30am on the first day of enrolment through the Leisure Link Internet Booking service (leisurelink.lcsd.gov.hk). The course fee is $20. Please visit the LCSD website (www.lcsd.gov.hk/en/visavis) or call 2414 5555 for details.
The Online Interactive Sports Training Programmes are part of the interactive “vis-a-vis +01” series under the LCSD Edutainment Channel (www.lcsd.gov.hk/edutainment/en) which promotes leisure, sports and culture through a one-stop online platform covering informative and learning materials.
Mar 2, 2021 | Business, Health and Wellness
More than 1.47 Cr COVID19 vaccine doses administered
4.27 lakh vaccine doses given till 7pm today
Posted On: 01 MAR 2021 9:45PM by PIB Delhi
The cumulative number of COVID19 vaccine doses administered in the country has crossed 1.47 Crore today.
The countrywide vaccination drive was rolled out on 16th Jan 2021 and vaccination of the Frontline Workers (FLWs) started from 2nd Feb 2021. The next phase of COVID-19 vaccination has commenced from today for those who are over 60 years of age and for people aged 45 and above with specified co-morbid conditions.
25 Lakh potential beneficiaries registered on the Co-Win portal today. Out of this, 24.5 Lakh are citizens and the rest are Healthcare Workers and Frontline Workers. About 6.44 Lakh appointments were booked today by the citizen beneficiaries.
A total of 1,47,28,569 vaccine doses have been given, as per the provisional report till 7 pm today.
These include 66,95,665 HCWs who have taken the 1st dose and 25,57,837 HCWs who have taken the 2nd dose, 53,27,587 FLWs (1st dose), 1,28,630 beneficiaries more than 60 years old and 18,850 beneficiaries aged 45 and above with specific co-morbidities.
Total 4,27,072 vaccine doses were given till 7 pm today, the forty fifth day of nationwide COVID19 vaccination. Out of which 3,25,485 beneficiaries were vaccinated for 1st dose and 1,01,587 HCWs received 2nd dose of vaccine as per the provisional report. Final reports would be completed for the day by late tonight.
|
Date: 1st March, 2021
|
|
HCWs
|
FLWs
|
45 to <60 years with Co-morbidities
|
Over 60 years
|
Total Achievement
|
|
1st Dose
|
2nd Dose
|
1st Dose
|
1st Dose
|
1st Dose
|
1st Dose
|
2nd Dose
|
|
25,656
|
1,01,587
|
1,52,349
|
18,850
|
1,28,630
|
3,25,485
|
1,01,587
|
